Briefing: Bacterial strain breaks decades-old bottleneck in chemotherapy drug manufacturing
Strategic angle: An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent.
Briefing: Trump's Influence on Drug Prices: A Closer Look
Strategic angle: Exploring the ongoing battle over drug pricing and the contrasting approaches of Trump and Biden.
Poll: Public Worries About Prescription Drug Costs Reach New High
Most Across Political Parties Want Government to Do More to Regulate Prices
Briefing: Trump is getting more credit than Biden for efforts to lower drug prices
Strategic angle: Trump is drawing more attention to his efforts to lower drug prices, like TrumpRx.
Briefing: Failed experiment leads to surprise drug development breakthrough
Strategic angle: Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than toxic chemicals.
Briefing: Trump touts cutting drug prices, slams fellow Republican Rep. Massie during stops in Ohio, Kentucky
Strategic angle: Trump emphasizes his commitment to lowering drug prices while criticizing Rep. Massie during campaign stops.
Briefing: Key Facts About Medicare Drug Price Negotiation
Strategic angle: The federal government negotiates prices for high-cost drugs under Medicare Part B and Part D.
FDA Approves Leucovorin as First Drug for Rare Genetic Disorder
This approval follows previous claims of its potential use in treating autism symptoms.
Briefing: Opinion: I’m a medical student. RFK Jr. is right about medical school and preventive care
Strategic angle: In medical school, a student writes, she has learned to react first, focus on prevention later.
Briefing: Meissa: Multi-modal Medical Agentic Intelligence
Strategic angle: Exploring the advancements in multi-modal large language models for medical applications.
Briefing: Mining the dark transcriptome: Synthesizing the first potential drug molecules from long noncoding RNA
Strategic angle: A team from University of Toronto Engineering pioneers a new approach to drug discovery by synthesizing long noncoding RNA outside the cell.
Briefing: GOP Senator Investigates FDA Over Rare Disease Drug Rejections
Strategic angle: Sen. Ron Johnson raises concerns about the FDA's handling of treatments for rare diseases after discussions with Commissioner Marty Makary.
Briefing: What’s next for RFK Jr.’s MAHA allies on vaccine policy?
Strategic angle: A coalition of Kennedy's allies gathered to discuss vaccines, but the health secretary was rarely mentioned.
BioNTech Founders to Depart, Form New mRNA-Focused Company
Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.
Briefing: Golfer Woodland opens up about PTSD diagnosis
Strategic angle: Gary Woodland reveals his struggle with post-traumatic stress disorder following brain surgery.
Briefing: Vertex says its drug successfully reduced marker of kidney disease in late-stage trial
Strategic angle: Vertex reported that its drug, acquired for $4.9 billion, halved a key marker of IgA nephropathy in late-stage trials.
Briefing: CRISPR-based technique unlocks healing power of mitochondria for heart failure therapy
Strategic angle: A groundbreaking approach using CRISPR technology shows promise in treating heart failure by enhancing mitochondrial function.
Briefing: Unlocking the hidden pocket on a billion‑dollar drug target
Strategic angle: Researchers discover new functions of the cereblon protein that could enhance cancer drug efficacy.
Briefing: A setback for Roche’s breast cancer drug
Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news
Servier's $2.5 Billion Acquisition of Day One: Strategic Implications
Servier's acquisition of Day One Biopharmaceuticals for $2.5 billion could reshape its position in the pediatric oncology market, but risks remain.